NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.43
0.10 (3.00%)
▲
5d:
+3.63%
30d:
-3.11%
90d:
-24.12%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NAGE trading at deep discount. Market pricing in -15.2% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: NAGE trading at deep discount. Market pricing in -15.2% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.82
49.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.43, which is considered slightly low relative to its 30-day fair value range of $3.39 to $3.72. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.2) compared to its historical average (18.5). Remarkably, the market is currently pricing in an annual earnings decline of 15.2% over the next few years. This pessimistic expectation contrasts with the company's recent 16.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.35. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.60 (+267.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.35. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.60 (+267.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.39 -
$3.72
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 267.3% below Wall St target ($12.60)
Trading Range Analysis
30-Day Trading Range
$3.39 -
$3.72
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.35
Resistance Level
$4.03
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.25
Wall Street Target
$12.60
(+267.3%)
Revenue Growth (YoY)
3.3%
Earnings Growth (YoY)
16.7%
Profit Margin
14.3%
Valuation Discount vs History
-15.2% cheaper
PE vs Historical
11.3 vs 18.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.2%
(market-implied from PE analysis)
1-Year Target
$3.09
(-10%)
2-Year Target
$2.78
(-19%)
3-Year Target
$2.50
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→19)
$4.11
(+20%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 32.6%)
$15.49
(+352%)
Base:
(SPY PE: 11.2, Growth: 32.6%)
$8.00
(+133%)
Bear:
(PE: 9.6, Growth: 32.6%)
$6.80
(+98%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 15.86 | Current EPS (TTM): $0.21
Bull Case
$5.32
(+55%)
Analyst growth 45.2%, PE expands to 17.4
Base Case
$4.84
(+41%)
Market implied 45.2%, PE stable at 15.9
Bear Case
$2.26
(-34%)
Severe decline -20.0%, PE contracts to 13.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.2 to 18.5
Stabilization Target:
$5.64
(+64.5%)
PE Expansion Potential:
+64.5%
Share & Embed Analysis
Last updated: July 03, 2026 4:57 PM ET
Data refreshes hourly during market hours. Next update: 5:57 PM
Data refreshes hourly during market hours. Next update: 5:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
